Adamis Pharmaceuticals Corporation. US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI ... Adamis Pharmaceuticals Describes Planned Response to ZIMHI ZIMHI is a 5 mg IM/SC (subcutaneous) product which was also approved in 2021 and is also not available for purchase at the time of this review. SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis' ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product. FDA Approvals Roundup: Tyrvaya, Zimhi, Biktarvy | RAPS Adamis has obtained the Food and Drug Administration's blessing for Zimhi (naloxone HCL Injection) 5 mg/0.5 mL product. The FDA has approved a higher-dose injectable formulation of the opioid antagonist naloxone (Zimhi - Adamis) for emergency treatment of opioid overdose.A single IM or SC injection of the new formulation delivers 5 mg of naloxone; injectable formulations that deliver 0.4 mg or 2 mg of the drug have been available for years. Adamis Receives FDA Approval for ZIMHI Zimhi (Naloxone Hydrochloride Injection): Uses, Dosage, Side Effects ... Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) stock soared after FDA approval for its drug ZIMHI. Zimhi's approval is noteworthy because some studies show that higher doses of naloxone are often needed to better treat synthetic opioid overdoses. ZIMHI may cause serious side effects, including sudden opioid withdrawal symptoms, which may include: body aches, fever, sweating, runny nose, sneezing, goose bumps, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, stomach cramping, increased blood pressure, or increased heart rate.